Zonisamide

Generic name: Pronounced as (zoe nis' a mide)
Brand names
  • Zonegran®
Click on drug name to hear pronunciation

Medical Content Reviewed By HelloPharmacist Staff

Last Revised - 05/15/2020

Zonisamide is used in combination with other medications to treat certain types of seizures. Zonisamide is in a class of medications called anticonvulsants. It works by decreasing abnormal electrical activity in the brain.

Zonisamide comes as a capsule to take by mouth. It is usually taken once or twice a day with or without food. To help you remember to take zonisamide, take it at around the same time(s) every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take zonisamide exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.

Swallow the capsules whole; do not split, chew, or crush them.

Your doctor will probably start you on a low dose of zonisamide and gradually increase your dose, not more often than once every 2 weeks.

Zonisamide may help control your condition but will not cure it. It may take 2 weeks or longer before you feel the full benefit of zonisamide. Continue to take zonisamide even if you feel well. Do not stop taking zonisamide without talking to your doctor, even if you experience side effects such as unusual changes in behavior or mood. If you suddenly stop taking zonisamide, your seizures may become worse. Your doctor will probably decrease your dose gradually.

Your doctor or pharmacist will give you the manufacturer's patient information sheet (Medication Guide) when you begin treatment with zonisamide and each time you refill your prescription. Read the information carefully and ask your doctor or pharmacist if you have any questions. You can also visit the Food and Drug Administration (FDA) website (http://www.fda.gov/Drugs/DrugSafety/ucm085729.htm) or the manufacturer's website to obtain the Medication Guide.

This medication may be prescribed for other uses; ask your doctor or pharmacist for more information.

Before taking zonisamide,

  • tell your doctor and pharmacist if you are allergic to zonisamide, diuretics ('water pills'), oral medications for diabetes, sulfa drugs, or any other medications.

  • tell your doctor and pharmacist what prescription and nonprescription medications, vitamins, and nutritional supplements you are taking or plan to take. Be sure to mention any of the following: amiodarone (Cordarone, Pacerone);antifungals such as itraconazole (Sporanox) and ketoconazole (Nizoral); carbonic anhydrase inhibitors such as acetazolamide (Diamox) and methazolamide; clarithromycin (Biaxin, in Prevpac); diltiazem (Cardizem, Dilacor, Tiazac); erythromycin (E.E.S., E-Mycin, Erythrocin); fluvoxamine (Luvox); HIV protease inhibitors such as indinavir (Crixivan), nelfinavir (Viracept), and ritonavir (Norvir, in Kaletra); medications for irritable bowel disease, motion sickness, Parkinson's disease, ulcers, or urinary problems; other medications for seizures including carbamazepine (Carbatrol, Epitol, Tegretol),phenobarbital (Luminal, Solfoton), phenytoin (Dilantin, Phenytek),and valproic acid (Depakene, Depakote); nefazodone (Serzone); hormonal contraceptives (birth control pills, patches, rings, and injections); pioglitazone (Actos, in Actoplus, in Duetact); rifabutin (Mycobutin); rifampin (Rifadin, Rimactane); troleandomycin (TAO) (not available in the U.S.); and verapamil (Calan, Covera, Isoptin, Verelan). Your doctor may need to change the doses of your medications or monitor you carefully for side effects.

  • tell your doctor what herbal products you are taking, especially St. John's wort.

  • tell your doctor if you are following a ketogenic diet (a high fat, low carbohydrate diet used to control seizures) or if you have or have ever had breathing problems, kidney liver, or lung disease. Also tell your doctor if you have diarrhea now, or if you develop diarrhea at any time during your treatment.

  • tell your doctor if you are pregnant or plan to become pregnant. You should use birth control to prevent pregnancy during your treatment. Talk to your doctor about birth control methods that will work for you. If you become pregnant while taking zonisamide, call your doctor.

  • tell your doctor if you are breast-feeding. If you breast-feed during your treatment, your baby may receive some zonisamide in the breast milk. Watch your baby closely for unusual sleepiness or poor weight gain.

  • if you are having surgery, including dental surgery, tell the doctor or dentist that you are taking zonisamide.

  • you should know that zonisamide may make you drowsy. Do not drive a car, operate machinery, or perform dangerous tasks until you know how this medication affects you.

  • you should know that zonisamide can decrease the body's ability to sweat and make it harder for your body to cool down when it gets very hot. This happens most often in warm weather and to children who take zonisamide. (Children should not normally take zonisamide, but in some cases, it may be prescribed by a doctor.) You should avoid exposure to heat and call your doctor right away if you have a fever and/or are not sweating as usual.

  • you should know that your mental health may change in unexpected ways and you may become suicidal (thinking about harming or killing yourself or planning or trying to do so) while you are taking zonisamide for the treatment of epilepsy, mental illness, or other conditions. A small number of adults and children 5 years of age and older (about 1 in 500 people) who took anticonvulsants such as zonisamide to treat various conditions during clinical studies became suicidal during their treatment. Some of these people developed suicidal thoughts and behavior as early as 1 week after they started taking the medication. There is a risk that you may experience changes in your mental health if you take an anticonvulsants medication such as zonisamide, but there may also be a risk that you will experience changes in your mental health if your condition is not treated. You and your doctor will decide whether the risks of taking an anticonvulsant medication are greater than the risks of not taking the medication. You, your family, or your caregiver should call your doctor right away if you experience any of the following symptoms: panic attacks; agitation or restlessness; new or worsening irritability, anxiety, or depression; acting on dangerous impulses; difficulty falling or staying asleep; aggressive, angry, or violent behavior; mania (frenzied, abnormally excited mood); talking or thinking about wanting to hurt yourself or end your life; withdrawing from friends and family; preoccupation with death and dying; giving away prized possessions; or any other unusual changes in behavior or mood. Be sure that your family or caregiver knows which symptoms may be serious so they can call the doctor if you are unable to seek treatment on your own.

Talk to your doctor about eating grapefruit and drinking grapefruit juice while taking this medicine.

Drink 6-8 glasses of water every day during your treatment with zonisamide.

Talk to your doctor about what to do if you miss a dose of zonisamide. Do not take a double dose to make up for a missed one.

  • Zonisamide may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:

    • nausea

    • vomiting

    • weight loss

    • changes in taste

    • diarrhea

    • constipation

    • heartburn

    • dry mouth

    • headache

    • dizziness

    • confusion

    • irritability

    • difficulty falling asleep or staying asleep

    • difficulty with memory

    • pain, burning, numbness, or tingling in the hands or feet

    • uncontrollable eye movements

    • double vision

  • Some side effects can be serious. The following symptoms are uncommon, but if you experience any of them, call your doctor immediately:

    • rash

    • blistering or peeling of skin

    • worsening or longer-lasting seizures

    • sudden back pain

    • stomach pain

    • pain when urinating

    • bloody or dark urine

    • fever, sore throat, chills, cough, and other signs of infection

    • sores in mouth

    • easy bruising

    • difficulty thinking of words or trouble speaking

    • difficulty thinking or concentrating

    • lack of coordination

    • difficulty walking

    • severe weakness

    • severe muscle pain

    • extreme tiredness

    • loss of appetite

    • fast, shallow breathing

    • irregular heartbeat

    • loss of consciousness

  • Zonisamide may cause other side effects. Call your doctor if you have any unusual problems while taking this medication.

  • Zonisamide may cause metabolic acidosis (abnormally low levels of a certain natural substance in the blood). Metabolic acidosis that is left untreated for a long time may increase the risk that other medical problems, including kidney stones and bone problems that may lead to fractures, will develop. Untreated metabolic acidosis may also cause slowed growth and a decrease in final height in children. Talk to your doctor about the risks of taking zonisamide.

  • If you experience a serious side effect, you or your doctor may send a report to the Food and Drug Administration's (FDA) MedWatch Adverse Event Reporting program online (http://www.fda.gov/Safety/MedWatch) or by phone (1-800-332-1088).

Keep this medication in the container it came in, tightly closed, and out of reach of children. Store it at room temperature and away from light, excess heat and moisture (not in the bathroom).

Unneeded medications should be disposed of in special ways to ensure that pets, children, and other people cannot consume them. However, you should not flush this medication down the toilet. Instead, the best way to dispose of your medication is through a medicine take-back program. Talk to your pharmacist or contact your local garbage/recycling department to learn about take-back programs in your community. See the FDA's Safe Disposal of Medicines website (http://goo.gl/c4Rm4p) for more information if you do not have access to a take-back program.

It is important to keep all medication out of sight and reach of children as many containers (such as weekly pill minders and those for eye drops, creams, patches, and inhalers) are not child-resistant and young children can open them easily. To protect young children from poisoning, always lock safety caps and immediately place the medication in a safe location – one that is up and away and out of their sight and reach. http://www.upandaway.org

In case of overdose, call the poison control helpline at 1-800-222-1222. Information is also available online at https://www.poisonhelp.org/help. If the victim has collapsed, had a seizure, has trouble breathing, or can't be awakened, immediately call emergency services at 911.

Symptoms of overdose may include:

  • slow heartbeat

  • slowed breathing

  • dizziness

  • fainting

  • coma (loss of consciousness for a period of time)

Keep all appointments with your doctor and the laboratory. Your doctor may order certain lab tests to check your body's response to zonisamide.

Do not let anyone else take your medication. Ask your pharmacist any questions you have about refilling your prescription.

It is important for you to keep a written list of all of the prescription and nonprescription (over-the-counter) medicines you are taking, as well as any products such as vitamins, minerals, or other dietary supplements. You should bring this list with you each time you visit a doctor or if you are admitted to a hospital. It is also important information to carry with you in case of emergencies.

Drug Interaction
Moxifloxacin Moxifloxacin The risk or severity of QTc prolongation can be increased when Zonisamide is combined with Moxifloxacin.
Repaglinide Repaglinide The therapeutic efficacy of Repaglinide can be increased when used in combination with Zonisamide.
Insulin Glargine (rDNA origin) Injection Insulin Glargine (rDNA origin) Injection The therapeutic efficacy of Insulin glargine can be increased when used in combination with Zonisamide.
Delavirdine Delavirdine The metabolism of Zonisamide can be decreased when combined with Delavirdine.
Nevirapine Nevirapine The metabolism of Zonisamide can be decreased when combined with Nevirapine.
Atorvastatin Atorvastatin The metabolism of Atorvastatin can be decreased when combined with Zonisamide.
Dolasetron Dolasetron The risk or severity of QTc prolongation can be increased when Zonisamide is combined with Dolasetron.
Aminophylline Aminophylline Zonisamide may increase the excretion rate of Aminophylline which could result in a lower serum level and potentially a reduction in efficacy.
Anagrelide Anagrelide The risk or severity of QTc prolongation can be increased when Zonisamide is combined with Anagrelide.
Bisacodyl Bisacodyl The risk or severity of adverse effects can be increased when Zonisamide is combined with Bisacodyl.
Candesartan Candesartan The risk or severity of hyperkalemia can be increased when Zonisamide is combined with Candesartan.
Cilostazol Cilostazol The serum concentration of Cilostazol can be increased when it is combined with Zonisamide.
Clopidogrel Clopidogrel The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Zonisamide.
Diphenoxylate Diphenoxylate The risk or severity of adverse effects can be increased when Zonisamide is combined with Diphenoxylate.
Erythromycin and Sulfisoxazole Erythromycin and Sulfisoxazole The risk or severity of QTc prolongation and hypotension can be increased when Erythromycin is combined with Zonisamide.
Estrogen and Progestin (Oral Contraceptives) Estrogen and Progestin (Oral Contraceptives) Conjugated estrogens may increase the excretion rate of Zonisamide which could result in a lower serum level and potentially a reduction in efficacy.
Fenofibrate Fenofibrate Zonisamide may increase the excretion rate of Fenofibrate which could result in a lower serum level and potentially a reduction in efficacy.
Guanfacine Guanfacine The risk or severity of adverse effects can be increased when Zonisamide is combined with Guanfacine.
Magnesium Gluconate Magnesium Gluconate The risk or severity of hypotension can be increased when Zonisamide is combined with Magnesium gluconate.
Magnesium Hydroxide Magnesium Hydroxide The risk or severity of hypotension can be increased when Zonisamide is combined with Magnesium hydroxide.
Magnesium Oxide Magnesium Oxide The risk or severity of hypotension can be increased when Zonisamide is combined with Magnesium oxide.
Miglitol Miglitol The therapeutic efficacy of Miglitol can be increased when used in combination with Zonisamide.
Mycophenolate Mycophenolate Zonisamide may increase the excretion rate of Mycophenolic acid which could result in a lower serum level and potentially a reduction in efficacy.
Naratriptan Naratriptan The metabolism of Naratriptan can be decreased when combined with Zonisamide.
Olsalazine Olsalazine The risk or severity of adverse effects can be increased when Olsalazine is combined with Zonisamide.
Paregoric Paregoric The risk or severity of adverse effects can be increased when Morphine is combined with Zonisamide.
Penbutolol Penbutolol The risk or severity of bradycardia can be increased when Zonisamide is combined with Acebutolol.
Pentazocine Pentazocine The risk or severity of adverse effects can be increased when Pentazocine is combined with Zonisamide.
Polyethylene glycol-electrolyte solution (PEG-ES) Polyethylene glycol-electrolyte solution (PEG-ES) The risk or severity of adverse effects can be increased when Zonisamide is combined with Polyethylene glycol.
Potassium Potassium Potassium may increase the excretion rate of Zonisamide which could result in a lower serum level and potentially a reduction in efficacy.
Prednisone Prednisone Prednisone may increase the excretion rate of Zonisamide which could result in a lower serum level and potentially a reduction in efficacy.
Psyllium Psyllium The risk or severity of adverse effects can be increased when Zonisamide is combined with Plantago seed.
Ranitidine Ranitidine Ranitidine may increase the excretion rate of Zonisamide which could result in a lower serum level and potentially a reduction in efficacy.
Reserpine Reserpine The risk or severity of adverse effects can be increased when Reserpine is combined with Zonisamide.
Rizatriptan Rizatriptan The metabolism of Rizatriptan can be decreased when combined with Zonisamide.
Sumatriptan Sumatriptan The metabolism of Sumatriptan can be decreased when combined with Zonisamide.
Tacrolimus Tacrolimus Zonisamide may increase the immunosuppressive activities of Tacrolimus.
Tizanidine Tizanidine The risk or severity of adverse effects can be increased when Tizanidine is combined with Zonisamide.
Triamcinolone Triamcinolone The metabolism of Zonisamide can be increased when combined with Triamcinolone.
Zolmitriptan Zolmitriptan The metabolism of Zolmitriptan can be decreased when combined with Zonisamide.
Ampicillin Injection Ampicillin Injection Ampicillin may increase the excretion rate of Zonisamide which could result in a lower serum level and potentially a reduction in efficacy.
Doxycycline Injection Doxycycline Injection Doxycycline may increase the excretion rate of Zonisamide which could result in a lower serum level and potentially a reduction in efficacy.
Famotidine Injection Famotidine Injection The risk or severity of QTc prolongation can be increased when Zonisamide is combined with Famotidine.
Fluconazole Injection Fluconazole Injection The metabolism of Zonisamide can be decreased when combined with Fluconazole.
Foscarnet Injection Foscarnet Injection Foscarnet may decrease the excretion rate of Zonisamide which could result in a higher serum level.
Hydromorphone Injection Hydromorphone Injection The risk or severity of adverse effects can be increased when Hydromorphone is combined with Zonisamide.
Levofloxacin Injection Levofloxacin Injection Zonisamide may increase the excretion rate of Levofloxacin which could result in a lower serum level and potentially a reduction in efficacy.
Meperidine Injection Meperidine Injection The risk or severity of adverse effects can be increased when Meperidine is combined with Zonisamide.
Metoclopramide Injection Metoclopramide Injection The risk or severity of sedation can be increased when Zonisamide is combined with Metoclopramide.
Metronidazole Injection Metronidazole Injection The therapeutic efficacy of Metronidazole can be decreased when used in combination with Zonisamide.
Morphine Injection Morphine Injection The risk or severity of adverse effects can be increased when Morphine is combined with Zonisamide.
Pamidronate Injection Pamidronate Injection Pamidronic acid may decrease the excretion rate of Zonisamide which could result in a higher serum level.
Vancomycin Injection Vancomycin Injection Zonisamide may decrease the excretion rate of Vancomycin which could result in a higher serum level.
Zidovudine Injection Zidovudine Injection The metabolism of Zonisamide can be increased when combined with Zidovudine.
Altretamine Altretamine The risk or severity of adverse effects can be increased when Amphetamine is combined with Zonisamide.
Cefuroxime Cefuroxime Cefuroxime may decrease the excretion rate of Zonisamide which could result in a higher serum level.
Cyclosporine Cyclosporine The risk or severity of renal failure can be increased when Zonisamide is combined with Cyclosporine.
Ondansetron Ondansetron The risk or severity of adverse effects can be increased when Ondansetron is combined with Zonisamide.
Enoxaparin Injection Enoxaparin Injection The risk or severity of hyperkalemia can be increased when Zonisamide is combined with Enoxaparin.
Granisetron Granisetron The risk or severity of QTc prolongation can be increased when Zonisamide is combined with Granisetron.
Torsemide Torsemide Torasemide may increase the excretion rate of Zonisamide which could result in a lower serum level and potentially a reduction in efficacy.
Olanzapine Olanzapine The risk or severity of adverse effects can be increased when Olanzapine is combined with Zonisamide.
Alosetron Alosetron The risk or severity of adverse effects can be increased when Zonisamide is combined with Alosetron.
Dofetilide Dofetilide Zonisamide may increase the arrhythmogenic activities of Dofetilide.
Entacapone Entacapone The risk or severity of adverse effects can be increased when Entacapone is combined with Zonisamide.
Eprosartan Eprosartan The risk or severity of hyperkalemia can be increased when Eprosartan is combined with Zonisamide.
Hydroxychloroquine Hydroxychloroquine The therapeutic efficacy of Hydroxychloroquine can be decreased when used in combination with Zonisamide.
Meloxicam Meloxicam The therapeutic efficacy of Zonisamide can be decreased when used in combination with Meloxicam.
Orlistat Orlistat Orlistat can cause a decrease in the absorption of Zonisamide resulting in a reduced serum concentration and potentially a decrease in efficacy.
Oxcarbazepine Oxcarbazepine The metabolism of Zonisamide can be increased when combined with Oxcarbazepine.
Pantoprazole Pantoprazole The metabolism of Zonisamide can be decreased when combined with Pantoprazole.
Sevelamer Sevelamer Sevelamer can cause a decrease in the absorption of Zonisamide resulting in a reduced serum concentration and potentially a decrease in efficacy.
Telmisartan Telmisartan The metabolism of Zonisamide can be decreased when combined with Telmisartan.
Temozolomide Temozolomide Temozolomide may increase the excretion rate of Zonisamide which could result in a lower serum level and potentially a reduction in efficacy.
Zaleplon Zaleplon The risk or severity of adverse effects can be increased when Zonisamide is combined with Zaleplon.
Anakinra Anakinra The metabolism of Zonisamide can be increased when combined with Anakinra.
Desloratadine Desloratadine The risk or severity of adverse effects can be increased when Zonisamide is combined with Desloratadine.
Linezolid Linezolid The risk or severity of adverse effects can be increased when Linezolid is combined with Zonisamide.
Rivastigmine Rivastigmine Zonisamide may increase the bradycardic activities of Rivastigmine.
Trimipramine Trimipramine The serum concentration of Zonisamide can be increased when it is combined with Trimipramine.
Etanercept Injection Etanercept Injection The metabolism of Zonisamide can be increased when combined with Etanercept.
Glycopyrrolate Glycopyrrolate Zonisamide may increase the central nervous system depressant (CNS depressant) activities of Glycopyrronium.
Modafinil Modafinil The metabolism of Zonisamide can be decreased when combined with Modafinil.
Perindopril Perindopril Perindopril may increase the excretion rate of Zonisamide which could result in a lower serum level and potentially a reduction in efficacy.
Tenofovir Tenofovir Tenofovir may decrease the excretion rate of Zonisamide which could result in a higher serum level.
Choline Magnesium Trisalicylate Choline Magnesium Trisalicylate Choline magnesium trisalicylate may decrease the excretion rate of Zonisamide which could result in a higher serum level.
Sirolimus Sirolimus Zonisamide may increase the immunosuppressive activities of Sirolimus.
Dutasteride Dutasteride The metabolism of Dutasteride can be decreased when combined with Zonisamide.
Epinephrine Injection Epinephrine Injection The risk or severity of Cardiac Arrhythmia can be increased when Epinephrine is combined with Zonisamide.
Eplerenone Eplerenone Eplerenone may increase the excretion rate of Zonisamide which could result in a lower serum level and potentially a reduction in efficacy.
Escitalopram Escitalopram The risk or severity of adverse effects can be increased when Zonisamide is combined with Escitalopram.
Olmesartan Olmesartan The risk or severity of hyperkalemia can be increased when Olmesartan is combined with Zonisamide.
Adalimumab Injection Adalimumab Injection The metabolism of Zonisamide can be increased when combined with Adalimumab.
Aripiprazole Aripiprazole The risk or severity of adverse effects can be increased when Zonisamide is combined with Aripiprazole.
Atomoxetine Atomoxetine The risk or severity of adverse effects can be increased when Atomoxetine is combined with Zonisamide.
Dexmethylphenidate Dexmethylphenidate The risk or severity of adverse effects can be increased when Zonisamide is combined with Dexmethylphenidate.
Atazanavir Atazanavir Atazanavir may decrease the excretion rate of Zonisamide which could result in a higher serum level.
Almotriptan Almotriptan The metabolism of Almotriptan can be decreased when combined with Zonisamide.
Eletriptan Eletriptan The risk or severity of adverse effects can be increased when Eletriptan is combined with Zonisamide.
Mefloquine Mefloquine The therapeutic efficacy of Zonisamide can be decreased when used in combination with Mefloquine.
Polyethylene Glycol 3350 Polyethylene Glycol 3350 The risk or severity of adverse effects can be increased when Zonisamide is combined with Polyethylene glycol.
Rosuvastatin Rosuvastatin The metabolism of Rosuvastatin can be decreased when combined with Zonisamide.
Vardenafil Vardenafil The serum concentration of Vardenafil can be increased when it is combined with Zonisamide.
Alfuzosin Alfuzosin The risk or severity of hypotension can be increased when Alfuzosin is combined with Zonisamide.
Aprepitant Aprepitant The metabolism of Zonisamide can be decreased when combined with Aprepitant.
Emtricitabine Emtricitabine Emtricitabine may increase the excretion rate of Zonisamide which could result in a lower serum level and potentially a reduction in efficacy.
Memantine Memantine The excretion of Memantine can be decreased when combined with Zonisamide.
Tegaserod Tegaserod The serum concentration of Tegaserod can be increased when it is combined with Zonisamide.
Tadalafil Tadalafil Tadalafil may increase the excretion rate of Zonisamide which could result in a lower serum level and potentially a reduction in efficacy.
Frovatriptan Frovatriptan The risk or severity of adverse effects can be increased when Zonisamide is combined with Frovatriptan.
Gemifloxacin Gemifloxacin The risk or severity of QTc prolongation can be increased when Zonisamide is combined with Gemifloxacin.
Progesterone Progesterone The metabolism of Progesterone can be increased when combined with Zonisamide.
Apomorphine Injection Apomorphine Injection The risk or severity of adverse effects can be increased when Apomorphine is combined with Zonisamide.
Infliximab Injection Infliximab Injection The metabolism of Zonisamide can be increased when combined with Infliximab.
Protriptyline Protriptyline The risk or severity of adverse effects can be increased when Protriptyline is combined with Zonisamide.
Rifaximin Rifaximin The serum concentration of Rifaximin can be increased when it is combined with Zonisamide.
Duloxetine Duloxetine The risk or severity of adverse effects can be increased when Zonisamide is combined with Duloxetine.
Norethindrone Norethindrone The metabolism of Zonisamide can be increased when combined with Norethisterone.
Tinidazole Tinidazole Zonisamide may increase the excretion rate of Tinidazole which could result in a lower serum level and potentially a reduction in efficacy.
Trospium Trospium Zonisamide may increase the central nervous system depressant (CNS depressant) activities of Trospium.
Cefditoren Cefditoren Cefdinir may increase the excretion rate of Zonisamide which could result in a lower serum level and potentially a reduction in efficacy.
Cyanocobalamin Injection Cyanocobalamin Injection Hydroxocobalamin may increase the excretion rate of Zonisamide which could result in a lower serum level and potentially a reduction in efficacy.
Erlotinib Erlotinib The metabolism of Erlotinib can be decreased when combined with Zonisamide.
Eszopiclone Eszopiclone The risk or severity of CNS depression can be increased when Zonisamide is combined with Eszopiclone.
Ganciclovir Ganciclovir Zonisamide may increase the excretion rate of Ganciclovir which could result in a lower serum level and potentially a reduction in efficacy.
Insulin Aspart (rDNA Origin) Injection Insulin Aspart (rDNA Origin) Injection The therapeutic efficacy of Insulin aspart can be increased when used in combination with Zonisamide.
Ribavirin Ribavirin Ribavirin may increase the excretion rate of Zonisamide which could result in a lower serum level and potentially a reduction in efficacy.
Solifenacin Solifenacin Zonisamide may increase the central nervous system depressant (CNS depressant) activities of Solifenacin.
Valganciclovir Valganciclovir Zonisamide may increase the excretion rate of Valganciclovir which could result in a lower serum level and potentially a reduction in efficacy.
Voriconazole Voriconazole The metabolism of Zonisamide can be decreased when combined with Voriconazole.
Adefovir Adefovir Adefovir may decrease the excretion rate of Zonisamide which could result in a higher serum level.
Dextroamphetamine Dextroamphetamine The risk or severity of adverse effects can be increased when Amphetamine is combined with Zonisamide.
Pramlintide Injection Pramlintide Injection The therapeutic efficacy of Pramlintide can be increased when used in combination with Zonisamide.
Sodium Oxybate Sodium Oxybate Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Zonisamide.
Exenatide Injection Exenatide Injection The therapeutic efficacy of Exenatide can be increased when used in combination with Zonisamide.
Ibandronate Ibandronate The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Zonisamide.
Isocarboxazid Isocarboxazid The risk or severity of adverse effects can be increased when Zonisamide is combined with Isocarboxazid.
Ramelteon Ramelteon The risk or severity of adverse effects can be increased when Zonisamide is combined with Ramelteon.
Darifenacin Darifenacin Zonisamide may increase the central nervous system depressant (CNS depressant) activities of Darifenacin.
Fentanyl Fentanyl The risk or severity of adverse effects can be increased when Fentanyl is combined with Zonisamide.
Pregabalin Pregabalin The therapeutic efficacy of Zonisamide can be increased when used in combination with Pregabalin.
Deferasirox Deferasirox The metabolism of Zonisamide can be decreased when combined with Deferasirox.
Phenylephrine Phenylephrine The risk or severity of hypertension can be decreased when Zonisamide is combined with Phenylephrine.
Tipranavir Tipranavir The metabolism of Zonisamide can be decreased when combined with Tipranavir.
Felbamate Felbamate The risk or severity of adverse effects can be increased when Zonisamide is combined with Felbamate.
Insulin Detemir (rDNA Origin) Injection Insulin Detemir (rDNA Origin) Injection The therapeutic efficacy of Insulin detemir can be increased when used in combination with Zonisamide.
Ranolazine Ranolazine The serum concentration of Ranolazine can be increased when it is combined with Zonisamide.
Abatacept Injection Abatacept Injection The metabolism of Zonisamide can be increased when combined with Abatacept.
Rasagiline Rasagiline Zonisamide may increase the excretion rate of Rasagiline which could result in a lower serum level and potentially a reduction in efficacy.
Imatinib Imatinib The risk or severity of QTc prolongation can be increased when Zonisamide is combined with Imatinib.
Sitagliptin Sitagliptin The therapeutic efficacy of Sitagliptin can be increased when used in combination with Zonisamide.
Varenicline Varenicline Zonisamide may increase the excretion rate of Varenicline which could result in a lower serum level and potentially a reduction in efficacy.
Gefitinib Gefitinib The metabolism of Zonisamide can be decreased when combined with Gefitinib.
Albuterol Albuterol Zonisamide may increase the excretion rate of Salbutamol which could result in a lower serum level and potentially a reduction in efficacy.
Paliperidone Paliperidone The risk or severity of QTc prolongation can be increased when Zonisamide is combined with Paliperidone.
Bortezomib Bortezomib The serum concentration of Zonisamide can be increased when it is combined with Bortezomib.
Clofarabine Injection Clofarabine Injection Clofarabine may increase the excretion rate of Zonisamide which could result in a lower serum level and potentially a reduction in efficacy.
Insulin Glulisine (rDNA origin) Injection Insulin Glulisine (rDNA origin) Injection The therapeutic efficacy of Insulin glulisine can be increased when used in combination with Zonisamide.
Lubiprostone Lubiprostone Zonisamide may increase the excretion rate of Lubiprostone which could result in a lower serum level and potentially a reduction in efficacy.
Oxaliplatin Injection Oxaliplatin Injection The risk or severity of QTc prolongation can be increased when Zonisamide is combined with Oxaliplatin.
Posaconazole Posaconazole The serum concentration of Posaconazole can be increased when it is combined with Zonisamide.
Primaquine Primaquine The risk or severity of QTc prolongation can be increased when Zonisamide is combined with Primaquine.
Aliskiren Aliskiren The risk or severity of hyperkalemia can be increased when Zonisamide is combined with Aliskiren.
Bismuth Subsalicylate Bismuth Subsalicylate The risk or severity of adverse effects can be increased when Bismuth subsalicylate is combined with Zonisamide.
Darunavir Darunavir The serum concentration of Zonisamide can be increased when it is combined with Darunavir.
Pemetrexed Injection Pemetrexed Injection Zonisamide may decrease the excretion rate of Pemetrexed which could result in a higher serum level.
Dimenhydrinate Dimenhydrinate The risk or severity of adverse effects can be increased when Zonisamide is combined with Dimenhydrinate.
Lisdexamfetamine Lisdexamfetamine Zonisamide may decrease the excretion rate of Lisdexamfetamine which could result in a higher serum level.
Nabilone Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Zonisamide.
Vorinostat Vorinostat The risk or severity of QTc prolongation can be increased when Zonisamide is combined with Vorinostat.
Sorafenib Sorafenib The metabolism of Zonisamide can be decreased when combined with Sorafenib.
Sunitinib Sunitinib The metabolism of Sunitinib can be decreased when combined with Zonisamide.
Dronabinol Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Zonisamide.
Lapatinib Lapatinib The metabolism of Lapatinib can be decreased when combined with Zonisamide.
Levocetirizine Levocetirizine The risk or severity of adverse effects can be increased when Zonisamide is combined with Levocetirizine.
Pegaptanib Injection Pegaptanib Injection Zonisamide may increase the excretion rate of Pegaptanib which could result in a lower serum level and potentially a reduction in efficacy.
Dasatinib Dasatinib The serum concentration of Dasatinib can be increased when it is combined with Zonisamide.
Mexiletine Mexiletine Mexiletine may increase the arrhythmogenic activities of Zonisamide.
Armodafinil Armodafinil The metabolism of Zonisamide can be decreased when combined with Armodafinil.
Azacitidine Injection Azacitidine Injection Zonisamide may increase the excretion rate of Azacitidine which could result in a lower serum level and potentially a reduction in efficacy.
Paclitaxel (with polyoxyethylated castor oil) Injection Paclitaxel (with polyoxyethylated castor oil) Injection The risk or severity of adverse effects can be increased when Zonisamide is combined with Castor oil.
Temsirolimus Temsirolimus The serum concentration of Temsirolimus can be increased when it is combined with Zonisamide.
Lenalidomide Lenalidomide Lenalidomide may increase the excretion rate of Zonisamide which could result in a lower serum level and potentially a reduction in efficacy.
Nilotinib Nilotinib The risk or severity of QTc prolongation can be increased when Zonisamide is combined with Nilotinib.
Toremifene Toremifene The risk or severity of QTc prolongation can be increased when Zonisamide is combined with Toremifene.
Budesonide Budesonide The metabolism of Budesonide can be increased when combined with Zonisamide.
Chloramphenicol Injection Chloramphenicol Injection The metabolism of Zonisamide can be decreased when combined with Chloramphenicol.
Desmopressin Desmopressin Desmopressin may increase the excretion rate of Zonisamide which could result in a lower serum level and potentially a reduction in efficacy.
OnabotulinumtoxinA Injection OnabotulinumtoxinA Injection The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Zonisamide.
RimabotulinumtoxinB Injection RimabotulinumtoxinB Injection The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Zonisamide.
Doripenem Injection Doripenem Injection Zonisamide may increase the excretion rate of Doripenem which could result in a lower serum level and potentially a reduction in efficacy.
Etravirine Etravirine The metabolism of Zonisamide can be decreased when combined with Etravirine.
Arsenic Trioxide Injection Arsenic Trioxide Injection The risk or severity of QTc prolongation can be increased when Zonisamide is combined with Arsenic trioxide.
Desvenlafaxine Desvenlafaxine The risk or severity of adverse effects can be increased when Zonisamide is combined with Desvenlafaxine.
Cevimeline Cevimeline Cevimeline may increase the excretion rate of Zonisamide which could result in a lower serum level and potentially a reduction in efficacy.
Nebivolol Nebivolol The risk or severity of bradycardia can be increased when Zonisamide is combined with Nebivolol.
Tretinoin Tretinoin The metabolism of Zonisamide can be decreased when combined with Tretinoin.
Bendamustine Injection Bendamustine Injection The serum concentration of Bendamustine can be increased when it is combined with Zonisamide.
Flecainide Flecainide The excretion of Flecainide can be decreased when combined with Zonisamide.
Certolizumab Injection Certolizumab Injection The metabolism of Zonisamide can be increased when combined with Certolizumab pegol.
Irinotecan Injection Irinotecan Injection The metabolism of Zonisamide can be decreased when combined with Irinotecan.
Daptomycin Injection Daptomycin Injection Daptomycin may increase the excretion rate of Zonisamide which could result in a lower serum level and potentially a reduction in efficacy.
Praziquantel Praziquantel The metabolism of Praziquantel can be decreased when combined with Zonisamide.
Methylnaltrexone Injection Methylnaltrexone Injection Zonisamide may increase the excretion rate of Methylnaltrexone which could result in a lower serum level and potentially a reduction in efficacy.
Rufinamide Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Zonisamide.
Silodosin Silodosin The serum concentration of Silodosin can be increased when it is combined with Zonisamide.
Midazolam Midazolam Midazolam may increase the excretion rate of Zonisamide which could result in a lower serum level and potentially a reduction in efficacy.
Naltrexone Injection Naltrexone Injection The therapeutic efficacy of Zonisamide can be decreased when used in combination with Naltrexone.
Dexrazoxane Injection Dexrazoxane Injection Dexrazoxane may increase the excretion rate of Zonisamide which could result in a lower serum level and potentially a reduction in efficacy.
Eltrombopag Eltrombopag The metabolism of Zonisamide can be decreased when combined with Eltrombopag.
Milnacipran Milnacipran The risk or severity of adverse effects can be increased when Zonisamide is combined with Milnacipran.
Dexlansoprazole Dexlansoprazole The metabolism of Dexlansoprazole can be decreased when combined with Zonisamide.
Plerixafor Injection Plerixafor Injection Zonisamide may increase the excretion rate of Plerixafor which could result in a lower serum level and potentially a reduction in efficacy.
Sodium Phosphate Sodium Phosphate Zonisamide may increase the nephrotoxic activities of Sodium phosphate, monobasic.
Fesoterodine Fesoterodine Zonisamide may increase the central nervous system depressant (CNS depressant) activities of Fesoterodine.
Degarelix Injection Degarelix Injection The risk or severity of QTc prolongation can be increased when Zonisamide is combined with Degarelix.
Betaxolol Betaxolol The risk or severity of bradycardia can be increased when Zonisamide is combined with Betaxolol.
Iloperidone Iloperidone The risk or severity of QTc prolongation can be increased when Zonisamide is combined with Iloperidone.
Prasugrel Prasugrel Zonisamide may increase the excretion rate of Prasugrel which could result in a lower serum level and potentially a reduction in efficacy.
Lacosamide Lacosamide The risk or severity of adverse effects can be increased when Zonisamide is combined with Lacosamide.
Everolimus Everolimus The serum concentration of Everolimus can be increased when it is combined with Zonisamide.
Tolvaptan (low blood sodium) Tolvaptan (low blood sodium) The serum concentration of Tolvaptan can be increased when it is combined with Zonisamide.
Dronedarone Dronedarone Dronedarone may increase the arrhythmogenic activities of Zonisamide.
AbobotulinumtoxinA Injection AbobotulinumtoxinA Injection The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Zonisamide.
Pralatrexate Injection Pralatrexate Injection Zonisamide may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy.
Palonosetron Injection Palonosetron Injection Palonosetron may increase the excretion rate of Zonisamide which could result in a lower serum level and potentially a reduction in efficacy.
Saxagliptin Saxagliptin The therapeutic efficacy of Saxagliptin can be increased when used in combination with Zonisamide.
Telavancin Injection Telavancin Injection The risk or severity of QTc prolongation can be increased when Zonisamide is combined with Telavancin.
Romidepsin Injection Romidepsin Injection The serum concentration of Romidepsin can be increased when it is combined with Zonisamide.
Tapentadol Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Zonisamide.
Topotecan Topotecan The serum concentration of Topotecan can be increased when it is combined with Zonisamide.
Golimumab Injection Golimumab Injection The metabolism of Zonisamide can be increased when combined with Golimumab.
Pazopanib Pazopanib The serum concentration of Pazopanib can be increased when it is combined with Zonisamide.
Asenapine Asenapine The risk or severity of QTc prolongation can be increased when Zonisamide is combined with Asenapine.
Vigabatrin Vigabatrin The risk or severity of adverse effects can be increased when Zonisamide is combined with Vigabatrin.
Albendazole Albendazole The metabolism of Albendazole can be decreased when combined with Zonisamide.
Ulipristal Ulipristal The metabolism of Ulipristal can be increased when combined with Zonisamide.
Levonorgestrel Levonorgestrel The metabolism of Zonisamide can be increased when combined with Levonorgestrel.
Oxymorphone Oxymorphone The risk or severity of adverse effects can be increased when Zonisamide is combined with Oxymorphone.
Liraglutide Injection Liraglutide Injection The therapeutic efficacy of Liraglutide can be increased when used in combination with Zonisamide.
Tocilizumab Injection Tocilizumab Injection The metabolism of Zonisamide can be increased when combined with Tocilizumab.
Dalfampridine Dalfampridine Zonisamide may increase the excretion rate of Dalfampridine which could result in a lower serum level and potentially a reduction in efficacy.
Fingolimod Fingolimod Zonisamide may increase the bradycardic activities of Fingolimod.
Eribulin Injection Eribulin Injection The risk or severity of QTc prolongation can be increased when Zonisamide is combined with Eribulin.
IncobotulinumtoxinA Injection IncobotulinumtoxinA Injection The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Zonisamide.
Cabazitaxel Injection Cabazitaxel Injection The serum concentration of Cabazitaxel can be increased when it is combined with Zonisamide.
Ceftaroline Injection Ceftaroline Injection Ceftaroline fosamil may decrease the excretion rate of Zonisamide which could result in a higher serum level.
Lurasidone Lurasidone The risk or severity of adverse effects can be increased when Zonisamide is combined with Lurasidone.
Acetaminophen Injection Acetaminophen Injection Acetaminophen may increase the excretion rate of Zonisamide which could result in a lower serum level and potentially a reduction in efficacy.
Vilazodone Vilazodone The risk or severity of adverse effects can be increased when Zonisamide is combined with Vilazodone.
Ipilimumab Injection Ipilimumab Injection Zonisamide may increase the excretion rate of Ipilimumab which could result in a lower serum level and potentially a reduction in efficacy.
Denileukin Diftitox Injection Denileukin Diftitox Injection Aldesleukin may increase the excretion rate of Zonisamide which could result in a lower serum level and potentially a reduction in efficacy.
Terbutaline Injection Terbutaline Injection Terbutaline may increase the excretion rate of Zonisamide which could result in a lower serum level and potentially a reduction in efficacy.
Azilsartan Azilsartan The risk or severity of hyperkalemia can be increased when Zonisamide is combined with Azilsartan medoxomil.
Roflumilast Roflumilast Zonisamide may increase the excretion rate of Roflumilast which could result in a lower serum level and potentially a reduction in efficacy.
Linagliptin Linagliptin The serum concentration of Linagliptin can be increased when it is combined with Zonisamide.
Rilpivirine Rilpivirine The risk or severity of QTc prolongation can be increased when Zonisamide is combined with Rilpivirine.
Telaprevir Telaprevir The metabolism of Zonisamide can be decreased when combined with Glecaprevir.
Potassium Iodide Potassium Iodide Potassium Iodide may increase the hyperkalemic activities of Zonisamide.
Cyclophosphamide Injection Cyclophosphamide Injection The metabolism of Cyclophosphamide can be decreased when combined with Zonisamide.
Abiraterone Abiraterone The metabolism of Zonisamide can be decreased when combined with Abiraterone.
Triptorelin Injection Triptorelin Injection The risk or severity of QTc prolongation can be increased when Zonisamide is combined with Triptorelin.
Rivaroxaban Rivaroxaban The serum concentration of Rivaroxaban can be increased when it is combined with Zonisamide.
Ticagrelor Ticagrelor The serum concentration of Ticagrelor can be increased when it is combined with Zonisamide.
Brentuximab Vedotin Injection Brentuximab Vedotin Injection The serum concentration of Brentuximab vedotin can be increased when it is combined with Zonisamide.
Ruxolitinib Ruxolitinib Ruxolitinib may increase the bradycardic activities of Zonisamide.
Vandetanib Vandetanib The risk or severity of QTc prolongation can be increased when Zonisamide is combined with Vandetanib.
Clobazam Clobazam The serum concentration of Clobazam can be increased when it is combined with Zonisamide.
Vemurafenib Vemurafenib The risk or severity of QTc prolongation can be increased when Zonisamide is combined with Vemurafenib.
Vismodegib Vismodegib The metabolism of Zonisamide can be decreased when combined with Vismodegib.
Ivacaftor Ivacaftor The metabolism of Ivacaftor can be decreased when combined with Zonisamide.
Deferiprone Deferiprone Zonisamide may increase the excretion rate of Deferiprone which could result in a lower serum level and potentially a reduction in efficacy.
Axitinib Axitinib The serum concentration of Axitinib can be increased when it is combined with Zonisamide.
Crizotinib Crizotinib The serum concentration of Crizotinib can be increased when it is combined with Zonisamide.
Cabergoline Cabergoline The serum concentration of Zonisamide can be increased when it is combined with Cabergoline.
Naloxone Injection Naloxone Injection Zonisamide may increase the excretion rate of Naloxone which could result in a lower serum level and potentially a reduction in efficacy.
Ambrisentan Ambrisentan The serum concentration of Ambrisentan can be increased when it is combined with Zonisamide.
Fondaparinux Injection Fondaparinux Injection Fondaparinux may increase the excretion rate of Zonisamide which could result in a lower serum level and potentially a reduction in efficacy.
Ezogabine Ezogabine The risk or severity of adverse effects can be increased when Tiagabine is combined with Zonisamide.
Carfilzomib Injection Carfilzomib Injection The serum concentration of Carfilzomib can be increased when it is combined with Zonisamide.
Enzalutamide Enzalutamide The metabolism of Enzalutamide can be increased when combined with Zonisamide.
Mirabegron Mirabegron The serum concentration of Mirabegron can be increased when it is combined with Zonisamide.
Regorafenib Regorafenib The serum concentration of Zonisamide can be increased when it is combined with Regorafenib.
Bosutinib Bosutinib The serum concentration of Bosutinib can be increased when it is combined with Zonisamide.
Linaclotide Linaclotide The risk or severity of adverse effects can be increased when Zonisamide is combined with Linaclotide.
Lorcaserin Lorcaserin The therapeutic efficacy of Mecasermin can be increased when used in combination with Zonisamide.
Teduglutide Injection Teduglutide Injection Zonisamide may increase the excretion rate of Teduglutide which could result in a lower serum level and potentially a reduction in efficacy.
Bedaquiline Bedaquiline The risk or severity of QTc prolongation can be increased when Zonisamide is combined with Bedaquiline.
Tofacitinib Tofacitinib Zonisamide may increase the bradycardic activities of Tofacitinib.
Alogliptin Alogliptin The therapeutic efficacy of Alogliptin can be increased when used in combination with Zonisamide.
Ponatinib Ponatinib The metabolism of Ponatinib can be decreased when combined with Zonisamide.
Pomalidomide Pomalidomide The serum concentration of Pomalidomide can be increased when it is combined with Zonisamide.
Ado-trastuzumab Emtansine Injection Ado-trastuzumab Emtansine Injection The serum concentration of Trastuzumab emtansine can be increased when it is combined with Zonisamide.
Apixaban Apixaban The serum concentration of Apixaban can be increased when it is combined with Zonisamide.
Canagliflozin Canagliflozin The therapeutic efficacy of Canagliflozin can be increased when used in combination with Zonisamide.
Methazolamide Methazolamide The risk or severity of adverse effects can be increased when Methazolamide is combined with Zonisamide.
Dabrafenib Dabrafenib The serum concentration of Zonisamide can be decreased when it is combined with Dabrafenib.
Trametinib Trametinib Zonisamide may increase the excretion rate of Trametinib which could result in a lower serum level and potentially a reduction in efficacy.
Dolutegravir Dolutegravir The serum concentration of Dolutegravir can be increased when it is combined with Zonisamide.
Afatinib Afatinib The serum concentration of Afatinib can be increased when it is combined with Zonisamide.
Levomilnacipran Levomilnacipran The risk or severity of adverse effects can be increased when Zonisamide is combined with Levomilnacipran.
Ertapenem Injection Ertapenem Injection Ertapenem may increase the excretion rate of Zonisamide which could result in a lower serum level and potentially a reduction in efficacy.
Vortioxetine Vortioxetine The metabolism of Vortioxetine can be decreased when combined with Zonisamide.
Perampanel Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Zonisamide.
Ibrutinib Ibrutinib The metabolism of Ibrutinib can be decreased when combined with Zonisamide.
Ketorolac Injection Ketorolac Injection Ketorolac may decrease the excretion rate of Zonisamide which could result in a higher serum level.
Simeprevir Simeprevir The serum concentration of Simeprevir can be increased when it is combined with Zonisamide.
Sofosbuvir Sofosbuvir The serum concentration of Sofosbuvir can be increased when it is combined with Zonisamide.
Dapagliflozin Dapagliflozin The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Zonisamide.
Apremilast Apremilast The metabolism of Zonisamide can be increased when combined with Apremilast.
Droxidopa Droxidopa The risk or severity of Cardiac Arrhythmia can be increased when Droxidopa is combined with Zonisamide.
Ceritinib Ceritinib Zonisamide may increase the bradycardic activities of Ceritinib.
Siltuximab Injection Siltuximab Injection The metabolism of Zonisamide can be increased when combined with Siltuximab.
Albiglutide Injection Albiglutide Injection The therapeutic efficacy of Albiglutide can be increased when used in combination with Zonisamide.
Eslicarbazepine Eslicarbazepine The risk or severity of adverse effects can be increased when Zonisamide is combined with Eslicarbazepine.
Belinostat Injection Belinostat Injection The serum concentration of Belinostat can be increased when it is combined with Zonisamide.
Idelalisib Idelalisib The serum concentration of Idelalisib can be increased when it is combined with Zonisamide.
Testosterone Injection Testosterone Injection Testosterone may increase the excretion rate of Zonisamide which could result in a lower serum level and potentially a reduction in efficacy.
Oritavancin Injection Oritavancin Injection The metabolism of Zonisamide can be decreased when combined with Oritavancin.
Empagliflozin Empagliflozin Zonisamide may increase the diuretic activities of Empagliflozin.
Hydrocodone Hydrocodone Zonisamide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Suvorexant Suvorexant Zonisamide may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Dulaglutide Injection Dulaglutide Injection The therapeutic efficacy of Dulaglutide can be increased when used in combination with Zonisamide.
Edoxaban Edoxaban The serum concentration of Edoxaban can be increased when it is combined with Zonisamide.
Olaparib Olaparib The metabolism of Olaparib can be decreased when combined with Zonisamide.
Methamphetamine Methamphetamine The risk or severity of adverse effects can be increased when Zonisamide is combined with Metamfetamine.
Tasimelteon Tasimelteon The risk or severity of adverse effects can be increased when Zonisamide is combined with Tasimelteon.
Lanreotide Injection Lanreotide Injection Zonisamide may increase the bradycardic activities of Lanreotide.
Nintedanib Nintedanib The serum concentration of Nintedanib can be increased when it is combined with Zonisamide.
Secukinumab Injection Secukinumab Injection The metabolism of Zonisamide can be increased when combined with Secukinumab.
Risperidone Injection Risperidone Injection The risk or severity of adverse effects can be increased when Risperidone is combined with Zonisamide.
Insulin Human Inhalation Insulin Human Inhalation The therapeutic efficacy of Insulin human can be increased when used in combination with Zonisamide.
Lenvatinib Lenvatinib The serum concentration of Lenvatinib can be increased when it is combined with Zonisamide.
Naloxegol Naloxegol The serum concentration of Naloxegol can be increased when it is combined with Zonisamide.
Panobinostat Panobinostat The serum concentration of Panobinostat can be increased when it is combined with Zonisamide.
Haloperidol Injection Haloperidol Injection The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Zonisamide.
Ivabradine Ivabradine Zonisamide may increase the bradycardic activities of Ivabradine.
Amiloride Amiloride Amiloride may increase the excretion rate of Zonisamide which could result in a lower serum level and potentially a reduction in efficacy.
Isavuconazonium Injection Isavuconazonium Injection The therapeutic efficacy of Isavuconazonium can be increased when used in combination with Zonisamide.
Macitentan Macitentan Zonisamide may increase the excretion rate of Macitentan which could result in a lower serum level and potentially a reduction in efficacy.
Flibanserin Flibanserin The risk or severity of adverse effects can be increased when Zonisamide is combined with Flibanserin.
Daclatasvir Daclatasvir The metabolism of Daclatasvir can be decreased when combined with Zonisamide.
Brexpiprazole Brexpiprazole The risk or severity of adverse effects can be increased when Zonisamide is combined with Brexpiprazole.
Ziprasidone Injection Ziprasidone Injection The risk or severity of QTc prolongation can be increased when Zonisamide is combined with Ziprasidone.
Cariprazine Cariprazine The risk or severity of adverse effects can be increased when Zonisamide is combined with Cariprazine.
Penicillin G Procaine Injection Penicillin G Procaine Injection Zonisamide may increase the excretion rate of Procaine benzylpenicillin which could result in a lower serum level and potentially a reduction in efficacy.
Eluxadoline Eluxadoline The therapeutic efficacy of Zonisamide can be decreased when used in combination with Eluxadoline.
Insulin Degludec (rDNA Origin) Injection Insulin Degludec (rDNA Origin) Injection The therapeutic efficacy of Insulin degludec can be increased when used in combination with Zonisamide.
Cobimetinib Cobimetinib The serum concentration of Cobimetinib can be increased when it is combined with Zonisamide.
Trabectedin Injection Trabectedin Injection The metabolism of Trabectedin can be decreased when combined with Zonisamide.
Osimertinib Osimertinib The serum concentration of Osimertinib can be increased when it is combined with Zonisamide.
Ixazomib Ixazomib Zonisamide may increase the excretion rate of Ixazomib which could result in a lower serum level and potentially a reduction in efficacy.
Rifapentine Rifapentine The metabolism of Zonisamide can be increased when combined with Rifapentine.
Lesinurad Lesinurad Zonisamide may increase the excretion rate of Lesinurad which could result in a lower serum level and potentially a reduction in efficacy.
Amphotericin B Liposomal Injection Amphotericin B Liposomal Injection Zonisamide may decrease the nephrotoxic activities of Amphotericin B.
Dexamethasone Injection Dexamethasone Injection The metabolism of Zonisamide can be increased when combined with Dexamethasone.
Brivaracetam Injection Brivaracetam Injection The risk or severity of adverse effects can be increased when Zonisamide is combined with Brivaracetam.
Venetoclax Venetoclax The serum concentration of Venetoclax can be increased when it is combined with Zonisamide.
Cobicistat Cobicistat The metabolism of Zonisamide can be decreased when combined with Cobicistat.
Midodrine Midodrine Midodrine may increase the bradycardic activities of Zonisamide.
Selexipag Selexipag The serum concentration of Selexipag can be increased when it is combined with Zonisamide.
Pimavanserin Pimavanserin The risk or severity of adverse effects can be increased when Zonisamide is combined with Pimavanserin.
Diphenhydramine Injection Diphenhydramine Injection The risk or severity of adverse effects can be increased when Zonisamide is combined with Diphenhydramine.
Furosemide Injection Furosemide Injection Furosemide may increase the excretion rate of Zonisamide which could result in a lower serum level and potentially a reduction in efficacy.
Rucaparib Rucaparib The metabolism of Zonisamide can be decreased when combined with Rucaparib.
Lixisenatide Injection Lixisenatide Injection The therapeutic efficacy of Lixisenatide can be increased when used in combination with Zonisamide.
Ribociclib Ribociclib The risk or severity of QTc prolongation can be increased when Zonisamide is combined with Ribociclib.
Doxepin (Insomnia) Doxepin (Insomnia) Zonisamide may increase the central nervous system depressant (CNS depressant) activities of Doxepin.
Plecanatide Plecanatide The risk or severity of adverse effects can be increased when Zonisamide is combined with Plecanatide.
Deutetrabenazine Deutetrabenazine The risk or severity of QTc prolongation can be increased when Zonisamide is combined with Deutetrabenazine.
Valbenazine Valbenazine Zonisamide may increase the excretion rate of Valbenazine which could result in a lower serum level and potentially a reduction in efficacy.
Deflazacort Deflazacort The metabolism of Zonisamide can be increased when combined with Deflazacort.
Safinamide Safinamide The risk or severity of adverse effects can be increased when Zonisamide is combined with Safinamide.
Naldemedine Naldemedine Zonisamide may increase the excretion rate of Naldemedine which could result in a lower serum level and potentially a reduction in efficacy.
Midostaurin Midostaurin The metabolism of Zonisamide can be increased when combined with Midostaurin.
Enasidenib Enasidenib The metabolism of Zonisamide can be decreased when combined with Enasidenib.
Inotuzumab Ozogamicin Injection Inotuzumab Ozogamicin Injection The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Zonisamide.
Benznidazole Benznidazole Zonisamide may increase the excretion rate of Benznidazole which could result in a lower serum level and potentially a reduction in efficacy.
Copanlisib Injection Copanlisib Injection The serum concentration of Copanlisib can be increased when it is combined with Zonisamide.
Delafloxacin Delafloxacin Zonisamide may increase the excretion rate of Delafloxacin which could result in a lower serum level and potentially a reduction in efficacy.
Abemaciclib Abemaciclib The serum concentration of Abemaciclib can be increased when it is combined with Zonisamide.
Betrixaban Betrixaban The serum concentration of Betrixaban can be increased when it is combined with Zonisamide.
Acalabrutinib Acalabrutinib The metabolism of Zonisamide can be decreased when combined with Acalabrutinib.
Letermovir Letermovir The metabolism of Zonisamide can be decreased when combined with Letermovir.
Semaglutide Injection Semaglutide Injection The therapeutic efficacy of Semaglutide can be increased when used in combination with Zonisamide.
Tetrabenazine Tetrabenazine The risk or severity of QTc prolongation can be increased when Zonisamide is combined with Tetrabenazine.
Ertugliflozin Ertugliflozin The metabolism of Zonisamide can be decreased when combined with Ertugliflozin.
Buprenorphine Injection Buprenorphine Injection Zonisamide may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Apalutamide Apalutamide The serum concentration of Zonisamide can be increased when it is combined with Apalutamide.
Fostamatinib Fostamatinib The metabolism of Zonisamide can be decreased when combined with Fostamatinib.
Avatrombopag Avatrombopag The serum concentration of Avatrombopag can be increased when it is combined with Zonisamide.
Baricitinib Baricitinib The serum concentration of Baricitinib can be increased when it is combined with Zonisamide.
Lofexidine Lofexidine The therapeutic efficacy of Zonisamide can be increased when used in combination with Lofexidine.
Plazomicin Injection Plazomicin Injection Zonisamide may decrease the excretion rate of Plazomicin which could result in a higher serum level.
Eliglustat Eliglustat The risk or severity of QTc prolongation can be increased when Zonisamide is combined with Eliglustat.
Encorafenib Encorafenib The risk or severity of QTc prolongation can be increased when Zonisamide is combined with Encorafenib.
Binimetinib Binimetinib The serum concentration of Binimetinib can be increased when it is combined with Zonisamide.
Ivosidenib Ivosidenib The serum concentration of Ivosidenib can be increased when it is combined with Zonisamide.
Lusutrombopag Lusutrombopag The serum concentration of Lusutrombopag can be increased when it is combined with Zonisamide.
Elagolix Elagolix The serum concentration of Elagolix can be increased when it is combined with Zonisamide.
Eravacycline Injection Eravacycline Injection The metabolism of Eravacycline can be decreased when combined with Zonisamide.
Doravirine Doravirine The metabolism of Doravirine can be decreased when combined with Zonisamide.
Cannabidiol Cannabidiol The risk or severity of adverse effects can be increased when Cannabidiol is combined with Zonisamide.
Dacomitinib Dacomitinib The serum concentration of Zonisamide can be increased when it is combined with Dacomitinib.
Duvelisib Duvelisib The serum concentration of Duvelisib can be increased when it is combined with Zonisamide.
Omadacycline Omadacycline The serum concentration of Omadacycline can be increased when it is combined with Zonisamide.
Stiripentol Stiripentol The metabolism of Zonisamide can be decreased when combined with Stiripentol.
Talazoparib Talazoparib The serum concentration of Talazoparib can be increased when it is combined with Zonisamide.
Gilteritinib Gilteritinib The serum concentration of Gilteritinib can be increased when it is combined with Zonisamide.
Glasdegib Glasdegib The risk or severity of QTc prolongation can be increased when Zonisamide is combined with Glasdegib.
Lorlatinib Lorlatinib The metabolism of Lorlatinib can be decreased when combined with Zonisamide.
Larotrectinib Larotrectinib The serum concentration of Larotrectinib can be increased when it is combined with Zonisamide.
Paclitaxel (with albumin) Injection Paclitaxel (with albumin) Injection The metabolism of Paclitaxel can be decreased when combined with Zonisamide.
Rifamycin Rifamycin The metabolism of Rifamycin can be increased when combined with Zonisamide.
Prucalopride Prucalopride The serum concentration of Prucalopride can be increased when it is combined with Zonisamide.
Magnesium Citrate Magnesium Citrate The risk or severity of hypotension can be increased when Zonisamide is combined with Magnesium citrate.
Emapalumab-lzsg Injection Emapalumab-lzsg Injection The metabolism of Zonisamide can be increased when combined with Emapalumab.
Acyclovir Ophthalmic Acyclovir Ophthalmic Acyclovir may decrease the excretion rate of Zonisamide which could result in a higher serum level.
Esomeprazole Injection Esomeprazole Injection The metabolism of Zonisamide can be decreased when combined with Esomeprazole.
Alpelisib Alpelisib The metabolism of Zonisamide can be decreased when combined with Alpelisib.
Brexanolone Injection Brexanolone Injection The risk or severity of adverse effects can be increased when Zonisamide is combined with Brexanolone.
Solriamfetol Solriamfetol The risk or severity of adverse effects can be increased when Zonisamide is combined with Solriamfetol.
Darolutamide Darolutamide The serum concentration of Darolutamide can be increased when it is combined with Zonisamide.
Triclabendazole Triclabendazole The metabolism of Zonisamide can be decreased when combined with Triclabendazole.
Entrectinib Entrectinib The risk or severity of QTc prolongation can be increased when Zonisamide is combined with Entrectinib.
Pexidartinib Pexidartinib The metabolism of Zonisamide can be decreased when combined with Pexidartinib.
Istradefylline Istradefylline The metabolism of Istradefylline can be decreased when combined with Zonisamide.
Pitolisant Pitolisant The serum concentration of Zonisamide can be decreased when it is combined with Pitolisant.
Fedratinib Fedratinib The serum concentration of Fedratinib can be increased when it is combined with Zonisamide.
Lefamulin Lefamulin Zonisamide may increase the QTc-prolonging activities of Lefamulin.
Phenytoin Injection Phenytoin Injection Phenytoin may increase the excretion rate of Zonisamide which could result in a lower serum level and potentially a reduction in efficacy.
Fosphenytoin Injection Fosphenytoin Injection Fosphenytoin may increase the excretion rate of Zonisamide which could result in a lower serum level and potentially a reduction in efficacy.
Enfortumab vedotin-ejfv Injection Enfortumab vedotin-ejfv Injection The serum concentration of Enfortumab vedotin can be increased when it is combined with Zonisamide.
Voxelotor Voxelotor The metabolism of Voxelotor can be decreased when combined with Zonisamide.
Lumateperone Lumateperone The risk or severity of adverse effects can be increased when Zonisamide is combined with Lumateperone.
Lasmiditan Lasmiditan The risk or severity of adverse effects can be increased when Zonisamide is combined with Lasmiditan.
Ubrogepant Ubrogepant The serum concentration of Ubrogepant can be increased when it is combined with Zonisamide.
Calcium Acetate Calcium Acetate The therapeutic efficacy of Zonisamide can be decreased when used in combination with Calcium acetate.
Tazemetostat Tazemetostat The serum concentration of Tazemetostat can be increased when it is combined with Zonisamide.
Cenobamate Cenobamate The serum concentration of Zonisamide can be decreased when it is combined with Cenobamate.
Selumetinib Selumetinib The serum concentration of Selumetinib can be increased when it is combined with Zonisamide.
Rimegepant Rimegepant The serum concentration of Rimegepant can be increased when it is combined with Zonisamide.
Tucatinib Tucatinib The metabolism of Tucatinib can be decreased when combined with Zonisamide.
Remdesivir Injection Remdesivir Injection The serum concentration of Remdesivir can be increased when it is combined with Zonisamide.
Ripretinib Ripretinib The serum concentration of Ripretinib can be increased when it is combined with Zonisamide.
Lemborexant Lemborexant The risk or severity of adverse effects can be increased when Zonisamide is combined with Lemborexant.
Fenfluramine Fenfluramine The risk or severity of adverse effects can be increased when Fenfluramine is combined with Zonisamide.
Fostemsavir Fostemsavir The serum concentration of Fostemsavir can be increased when it is combined with Zonisamide.
Octreotide Octreotide The serum concentration of the active metabolites of Zonisamide can be increased when Zonisamide is used in combination with Octreotide.
Belantamab Mafodotin-blmf Injection Belantamab Mafodotin-blmf Injection The serum concentration of Belantamab mafodotin can be increased when it is combined with Zonisamide.
Pralsetinib Pralsetinib The serum concentration of Pralsetinib can be increased when it is combined with Zonisamide.
Satralizumab-mwge Injection Satralizumab-mwge Injection The serum concentration of Zonisamide can be decreased when it is combined with Satralizumab.
Relugolix Relugolix The serum concentration of Relugolix can be increased when it is combined with Zonisamide.
Progestin-Only (drospirenone) Oral Contraceptives Progestin-Only (drospirenone) Oral Contraceptives The metabolism of Drospirenone can be increased when combined with Zonisamide.
Viloxazine Viloxazine Zonisamide may increase the excretion rate of Viloxazine which could result in a lower serum level and potentially a reduction in efficacy.
Tobramycin Injection Tobramycin Injection Tobramycin may decrease the excretion rate of Zonisamide which could result in a higher serum level.
Theophylline Theophylline Zonisamide may increase the excretion rate of Theophylline which could result in a lower serum level and potentially a reduction in efficacy.
Fenoprofen Fenoprofen Fenoprofen may decrease the excretion rate of Zonisamide which could result in a higher serum level.
Indomethacin Indomethacin The metabolism of Zonisamide can be decreased when combined with Indomethacin.
Mefenamic Acid Mefenamic Acid Mefenamic acid may decrease the excretion rate of Zonisamide which could result in a higher serum level.
Naproxen Naproxen Naproxen may decrease the excretion rate of Zonisamide which could result in a higher serum level.
Tolmetin Tolmetin Tolmetin may decrease the excretion rate of Zonisamide which could result in a higher serum level.
Sulindac Sulindac Sulindac may decrease the excretion rate of Zonisamide which could result in a higher serum level.
Trazodone Trazodone The risk or severity of QTc prolongation can be increased when Trazodone is combined with Zonisamide.
Isotretinoin Isotretinoin Zonisamide may increase the excretion rate of Isotretinoin which could result in a lower serum level and potentially a reduction in efficacy.
Sucralfate Sucralfate Sucralfate may increase the excretion rate of Zonisamide which could result in a lower serum level and potentially a reduction in efficacy.
Floxuridine Floxuridine Floxuridine may increase the excretion rate of Zonisamide which could result in a lower serum level and potentially a reduction in efficacy.
Phenobarbital Phenobarbital The metabolism of Phenobarbital can be decreased when combined with Zonisamide.
Metaxalone Metaxalone The risk or severity of adverse effects can be increased when Metaxalone is combined with Zonisamide.
Methotrexate Injection Methotrexate Injection The risk or severity of adverse effects can be increased when Zonisamide is combined with Methotrexate.
Levorphanol Levorphanol The risk or severity of adverse effects can be increased when Levorphanol is combined with Zonisamide.
Primidone Primidone The metabolism of Primidone can be decreased when combined with Zonisamide.
Methsuximide Methsuximide Zonisamide may increase the arrhythmogenic activities of Methsuximide.
Diethylpropion Diethylpropion The risk or severity of adverse effects can be increased when Zonisamide is combined with Diethylpropion.
Chlorpromazine Chlorpromazine The risk or severity of QTc prolongation can be increased when Zonisamide is combined with Chlorpromazine.
Diazepam Diazepam The risk or severity of adverse effects can be increased when Diazepam is combined with Zonisamide.
Oxazepam Oxazepam The risk or severity of adverse effects can be increased when Oxazepam is combined with Zonisamide.
Flurazepam Flurazepam The risk or severity of adverse effects can be increased when Flurazepam is combined with Zonisamide.
Clorazepate Clorazepate The risk or severity of adverse effects can be increased when Clorazepic acid is combined with Zonisamide.
Lorazepam Lorazepam The risk or severity of adverse effects can be increased when Lorazepam is combined with Zonisamide.
Phenoxybenzamine Phenoxybenzamine The risk or severity of hypotension can be increased when Phenoxybenzamine is combined with Zonisamide.
Carmustine Carmustine Carmustine may increase the excretion rate of Zonisamide which could result in a lower serum level and potentially a reduction in efficacy.
Amantadine Amantadine Zonisamide may increase the excretion rate of Amantadine which could result in a lower serum level and potentially a reduction in efficacy.
Codeine Codeine The risk or severity of adverse effects can be increased when Codeine is combined with Zonisamide.
Meprobamate Meprobamate The risk or severity of adverse effects can be increased when Meprobamate is combined with Zonisamide.
Chlordiazepoxide Chlordiazepoxide The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Zonisamide.
Bromocriptine Bromocriptine The risk or severity of adverse effects can be increased when Zonisamide is combined with Bromocriptine.
Tranylcypromine Tranylcypromine The metabolism of Zonisamide can be decreased when combined with Tranylcypromine.
Phenelzine Phenelzine The metabolism of Phenelzine can be decreased when combined with Zonisamide.
Procarbazine Procarbazine The risk or severity of adverse effects can be increased when Zonisamide is combined with Procarbazine.
Ergoloid Mesylates Ergoloid Mesylates The risk or severity of adverse effects can be increased when Zonisamide is combined with Ergoloid mesylate.
Tetracycline Tetracycline Tetracycline may increase the excretion rate of Zonisamide which could result in a lower serum level and potentially a reduction in efficacy.
Minocycline Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Zonisamide.
Prochlorperazine Prochlorperazine The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Zonisamide.
Thioridazine Thioridazine The risk or severity of QTc prolongation can be increased when Zonisamide is combined with Thioridazine.
Trifluoperazine Trifluoperazine The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Zonisamide.
Bleomycin Bleomycin Bleomycin may increase the excretion rate of Zonisamide which could result in a lower serum level and potentially a reduction in efficacy.
Dapsone Dapsone The metabolism of Zonisamide can be decreased when combined with Dapsone.
Sulfadiazine Sulfadiazine The therapeutic efficacy of Sulfadiazine can be increased when used in combination with Zonisamide.
Oxycodone Oxycodone The risk or severity of adverse effects can be increased when Oxycodone is combined with Zonisamide.
Methadone Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Zonisamide.
Oxybutynin Oxybutynin Zonisamide may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.
Benztropine Benztropine Zonisamide may increase the central nervous system depressant (CNS depressant) activities of Benzatropine.
Colestipol Colestipol Colestipol can cause a decrease in the absorption of Zonisamide resulting in a reduced serum concentration and potentially a decrease in efficacy.
Maprotiline Maprotiline Zonisamide may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Ibuprofen Ibuprofen Ibuprofen may decrease the excretion rate of Zonisamide which could result in a higher serum level.
Trihexyphenidyl Trihexyphenidyl Zonisamide may increase the central nervous system depressant (CNS depressant) activities of Trihexyphenidyl.
Orphenadrine Orphenadrine Zonisamide may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Perphenazine Perphenazine The risk or severity of adverse effects can be increased when Perphenazine is combined with Zonisamide.
Azathioprine Azathioprine Zonisamide may increase the excretion rate of Azathioprine which could result in a lower serum level and potentially a reduction in efficacy.
Fluphenazine Fluphenazine The risk or severity of adverse effects can be increased when Fluphenazine is combined with Zonisamide.
Phentermine Phentermine Zonisamide may decrease the excretion rate of Phentermine which could result in a higher serum level.
Methylphenidate Methylphenidate Methylphenidate may increase the excretion rate of Zonisamide which could result in a lower serum level and potentially a reduction in efficacy.
Amoxapine Amoxapine Zonisamide may increase the central nervous system depressant (CNS depressant) activities of Amoxapine.
Sulfasalazine Sulfasalazine The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Zonisamide.
Hydrocortisone Hydrocortisone The metabolism of Zonisamide can be decreased when combined with Hydrocortisone.
Doxorubicin Doxorubicin The serum concentration of Doxorubicin can be increased when it is combined with Zonisamide.
Dactinomycin Dactinomycin The serum concentration of Dactinomycin can be increased when it is combined with Zonisamide.
Phenazopyridine Phenazopyridine Phenazopyridine may decrease the excretion rate of Zonisamide which could result in a higher serum level.
Carbamazepine Carbamazepine Carbamazepine may increase the Change in thyroid function activities of Zonisamide.
Molindone Molindone The risk or severity of adverse effects can be increased when Zonisamide is combined with Molindone.
Methyldopa Methyldopa Zonisamide may increase the excretion rate of Methyldopa which could result in a lower serum level and potentially a reduction in efficacy.
Clonidine Clonidine The risk or severity of sedation can be increased when Clonidine is combined with Zonisamide.
Prazosin Prazosin The risk or severity of hypotension can be increased when Prazosin is combined with Zonisamide.
Hydralazine Hydralazine Zonisamide may increase the excretion rate of Hydralazine which could result in a lower serum level and potentially a reduction in efficacy.
Cimetidine Cimetidine The serum concentration of Zonisamide can be increased when it is combined with Cimetidine.
Gentamicin Injection Gentamicin Injection Gentamicin may decrease the excretion rate of Zonisamide which could result in a higher serum level.
Warfarin Warfarin Warfarin may decrease the excretion rate of Zonisamide which could result in a higher serum level.
Clonazepam Clonazepam The risk or severity of adverse effects can be increased when Zonisamide is combined with Clonazepam.
Loperamide Loperamide Zonisamide may increase the arrhythmogenic activities of Loperamide.
Promethazine Promethazine The risk or severity of adverse effects can be increased when Zonisamide is combined with Promethazine.
Meclofenamate Meclofenamate Meclofenamic acid may decrease the excretion rate of Zonisamide which could result in a higher serum level.
Daunorubicin Daunorubicin The metabolism of Zonisamide can be increased when combined with Daunorubicin.
Nitrofurantoin Nitrofurantoin Nitrofurantoin may increase the excretion rate of Zonisamide which could result in a lower serum level and potentially a reduction in efficacy.
Methenamine Methenamine The serum concentration of the active metabolites of Methenamine can be reduced when Methenamine is used in combination with Zonisamide resulting in a loss in efficacy.
Digoxin Digoxin Zonisamide may increase the arrhythmogenic activities of Digoxin.
Loxapine Loxapine The risk or severity of adverse effects can be increased when Loxapine is combined with Zonisamide.
Chloroquine Chloroquine The risk or severity of QTc prolongation can be increased when Zonisamide is combined with Chloroquine.
Quinine Quinine The excretion of Quinine can be decreased when combined with Zonisamide.
Ethosuximide Ethosuximide Ethosuximide may increase the arrhythmogenic activities of Zonisamide.
Triamterene Triamterene Triamterene may decrease the excretion rate of Zonisamide which could result in a higher serum level.
Lactulose Lactulose The risk or severity of adverse effects can be increased when Zonisamide is combined with Lactulose.
Chlorothiazide Chlorothiazide Chlorothiazide may increase the excretion rate of Zonisamide which could result in a lower serum level and potentially a reduction in efficacy.
Chlorthalidone Chlorthalidone Chlorthalidone may increase the excretion rate of Zonisamide which could result in a lower serum level and potentially a reduction in efficacy.
Metolazone Metolazone Metolazone may increase the excretion rate of Zonisamide which could result in a lower serum level and potentially a reduction in efficacy.
Isosorbide Isosorbide The metabolism of Zonisamide can be increased when combined with Isosorbide.
Clindamycin Injection Clindamycin Injection The metabolism of Clindamycin can be decreased when combined with Zonisamide.
Secobarbital Secobarbital The risk or severity of adverse effects can be increased when Secobarbital is combined with Zonisamide.
Desipramine Desipramine Zonisamide may increase the central nervous system depressant (CNS depressant) activities of Desipramine.
Amitriptyline Amitriptyline Zonisamide may increase the central nervous system depressant (CNS depressant) activities of Amitriptyline.
Imipramine Imipramine The serum concentration of Imipramine can be increased when it is combined with Zonisamide.
Probenecid Probenecid The metabolism of Zonisamide can be decreased when combined with Probenecid.
Quinidine Quinidine Zonisamide may increase the arrhythmogenic activities of Quinidine.
Procainamide Procainamide Zonisamide may increase the arrhythmogenic activities of Procainamide.
Isoniazid Isoniazid The metabolism of Zonisamide can be decreased when combined with Isoniazid.
Pyrazinamide Pyrazinamide Pyrazinamide may increase the excretion rate of Zonisamide which could result in a lower serum level and potentially a reduction in efficacy.
Rifampin Rifampin The metabolism of Zonisamide can be increased when combined with Rifampicin.
Disopyramide Disopyramide Zonisamide may increase the arrhythmogenic activities of Disopyramide.
Valproic Acid Valproic Acid The risk or severity of QTc prolongation can be increased when Zonisamide is combined with Valproic acid.
Tamoxifen Tamoxifen The metabolism of Zonisamide can be decreased when combined with Tamoxifen.
Butabarbital Butabarbital The risk or severity of adverse effects can be increased when Butabarbital is combined with Zonisamide.
Liothyronine Liothyronine Liothyronine may increase the excretion rate of Zonisamide which could result in a lower serum level and potentially a reduction in efficacy.
Methimazole Methimazole The metabolism of Zonisamide can be decreased when combined with Methimazole.
Chlorpropamide Chlorpropamide The therapeutic efficacy of Chlorpropamide can be increased when used in combination with Zonisamide.
Tolbutamide Tolbutamide The therapeutic efficacy of Tolbutamide can be increased when used in combination with Zonisamide.
Tolazamide Tolazamide The therapeutic efficacy of Tolazamide can be increased when used in combination with Zonisamide.
Dextromethorphan Dextromethorphan The risk or severity of adverse effects can be increased when Dextromethorphan is combined with Zonisamide.
Cyclobenzaprine Cyclobenzaprine The risk or severity of CNS depression can be increased when Zonisamide is combined with Cyclobenzaprine.
Baclofen Baclofen The risk or severity of adverse effects can be increased when Baclofen is combined with Zonisamide.
Doxylamine Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Zonisamide.
Cyproheptadine Cyproheptadine Zonisamide may increase the central nervous system depressant (CNS depressant) activities of Cyproheptadine.
Clemastine Clemastine The risk or severity of QTc prolongation can be increased when Zonisamide is combined with Clemastine.
Chlorpheniramine Chlorpheniramine The risk or severity of QTc prolongation can be increased when Zonisamide is combined with Chlorpheniramine.
Brompheniramine Brompheniramine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Zonisamide.
Meclizine Meclizine The risk or severity of adverse effects can be increased when Meclizine is combined with Zonisamide.
Ethambutol Ethambutol Ethambutol may increase the excretion rate of Zonisamide which could result in a lower serum level and potentially a reduction in efficacy.
Methyclothiazide Methyclothiazide Methyclothiazide may increase the excretion rate of Zonisamide which could result in a lower serum level and potentially a reduction in efficacy.
Hydrochlorothiazide Hydrochlorothiazide Hydrochlorothiazide may decrease the excretion rate of Zonisamide which could result in a higher serum level.
Dantrolene Dantrolene The risk or severity of hyperkalemia can be increased when Dantrolene is combined with Zonisamide.
Chlorzoxazone Chlorzoxazone The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Zonisamide.
Carisoprodol Carisoprodol The risk or severity of adverse effects can be increased when Carisoprodol is combined with Zonisamide.
Methocarbamol Methocarbamol The risk or severity of adverse effects can be increased when Methocarbamol is combined with Zonisamide.
Pyridoxine Pyridoxine Pyridoxine may increase the excretion rate of Zonisamide which could result in a lower serum level and potentially a reduction in efficacy.
Folic Acid Folic Acid Folic acid may increase the excretion rate of Zonisamide which could result in a lower serum level and potentially a reduction in efficacy.
Disulfiram Disulfiram The therapeutic efficacy of Zonisamide can be decreased when used in combination with Disulfiram.
Propranolol (Cardiovascular) Propranolol (Cardiovascular) The serum concentration of Propranolol can be increased when it is combined with Zonisamide.
Pseudoephedrine Pseudoephedrine Zonisamide may decrease the excretion rate of Pseudoephedrine which could result in a higher serum level.
Nortriptyline Nortriptyline The serum concentration of Nortriptyline can be increased when it is combined with Zonisamide.
Spironolactone Spironolactone Spironolactone may increase the excretion rate of Zonisamide which could result in a lower serum level and potentially a reduction in efficacy.
Amphotericin B Injection Amphotericin B Injection Zonisamide may decrease the nephrotoxic activities of Amphotericin B.
Mercaptopurine Mercaptopurine Zonisamide may increase the excretion rate of Mercaptopurine which could result in a lower serum level and potentially a reduction in efficacy.
Phytonadione Phytonadione Zonisamide may increase the excretion rate of Phylloquinone which could result in a lower serum level and potentially a reduction in efficacy.
Amikacin Injection Amikacin Injection Amikacin may decrease the excretion rate of Zonisamide which could result in a higher serum level.
Nadolol Nadolol The risk or severity of bradycardia can be increased when Zonisamide is combined with Nadolol.
Butorphanol Injection Butorphanol Injection The risk or severity of adverse effects can be increased when Butorphanol is combined with Zonisamide.
Nalbuphine Injection Nalbuphine Injection The risk or severity of adverse effects can be increased when Nalbuphine is combined with Zonisamide.
Cholestyramine Resin Cholestyramine Resin Cholestyramine can cause a decrease in the absorption of Zonisamide resulting in a reduced serum concentration and potentially a decrease in efficacy.
Allopurinol Allopurinol Allopurinol may increase the excretion rate of Zonisamide which could result in a lower serum level and potentially a reduction in efficacy.
Oxytocin Injection Oxytocin Injection The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Zonisamide.
Trimethobenzamide Trimethobenzamide The risk or severity of adverse effects can be increased when Trimethobenzamide is combined with Zonisamide.
Clomiphene Clomiphene The serum concentration of Clomifene can be increased when it is combined with Zonisamide.
Flavoxate Flavoxate Zonisamide may increase the central nervous system depressant (CNS depressant) activities of Flavoxate.
Papaverine Papaverine The risk or severity of QTc prolongation can be increased when Zonisamide is combined with Papaverine.
Fluorouracil Injection Fluorouracil Injection The risk or severity of QTc prolongation can be increased when Zonisamide is combined with Fluorouracil.
Colchicine Colchicine The serum concentration of Colchicine can be increased when it is combined with Zonisamide.
Cefaclor Cefaclor Cefaclor may decrease the excretion rate of Zonisamide which could result in a higher serum level.
Cefadroxil Cefadroxil Cefadroxil may decrease the excretion rate of Zonisamide which could result in a higher serum level.
Cefazolin Injection Cefazolin Injection Cefazolin may decrease the excretion rate of Zonisamide which could result in a higher serum level.
Cephalexin Cephalexin Cephalexin may decrease the excretion rate of Zonisamide which could result in a higher serum level.
Cefoxitin Injection Cefoxitin Injection Cefoxitin may decrease the excretion rate of Zonisamide which could result in a higher serum level.
Dacarbazine Dacarbazine Dacarbazine may increase the excretion rate of Zonisamide which could result in a lower serum level and potentially a reduction in efficacy.
Acetazolamide Acetazolamide The risk or severity of adverse effects can be increased when Acetazolamide is combined with Zonisamide.
Cefotaxime Injection Cefotaxime Injection Cefotaxime may decrease the excretion rate of Zonisamide which could result in a higher serum level.
Calcitonin Salmon Injection Calcitonin Salmon Injection Salmon calcitonin may increase the excretion rate of Zonisamide which could result in a lower serum level and potentially a reduction in efficacy.
Ketoconazole Ketoconazole The metabolism of Zonisamide can be decreased when combined with Ketoconazole.
Pyrantel Pyrantel The risk or severity of adverse effects can be increased when Zonisamide is combined with Pyrantel.
Vincristine Injection Vincristine Injection The excretion of Vincristine can be decreased when combined with Zonisamide.
Captopril Captopril The risk or severity of hyperkalemia can be increased when Zonisamide is combined with Captopril.
Vinblastine Vinblastine The serum concentration of Vinblastine can be increased when it is combined with Zonisamide.
Ethacrynic Acid Ethacrynic Acid Etacrynic acid may decrease the excretion rate of Zonisamide which could result in a higher serum level.
Colistimethate Injection Colistimethate Injection Colistimethate may decrease the excretion rate of Zonisamide which could result in a higher serum level.
Metoprolol Metoprolol The risk or severity of bradycardia can be increased when Zonisamide is combined with Metoprolol.
Hydroxyzine Hydroxyzine The risk or severity of QTc prolongation can be increased when Hydroxyzine is combined with Zonisamide.
Thiothixene Thiothixene The risk or severity of adverse effects can be increased when Zonisamide is combined with Thiothixene.
Aspirin Aspirin Acetylsalicylic acid may decrease the excretion rate of Zonisamide which could result in a higher serum level.
Salsalate Salsalate Salsalate may decrease the excretion rate of Zonisamide which could result in a higher serum level.
Chlorambucil Chlorambucil The therapeutic efficacy of Zonisamide can be decreased when used in combination with Chlorambucil.
Alprazolam Alprazolam Alprazolam may increase the excretion rate of Zonisamide which could result in a lower serum level and potentially a reduction in efficacy.
Temazepam Temazepam The risk or severity of adverse effects can be increased when Temazepam is combined with Zonisamide.
Triazolam Triazolam Triazolam may increase the excretion rate of Zonisamide which could result in a lower serum level and potentially a reduction in efficacy.
Dicyclomine Dicyclomine Zonisamide may increase the central nervous system depressant (CNS depressant) activities of Dicyclomine.
Hyoscyamine Hyoscyamine Zonisamide may increase the arrhythmogenic activities of Hyoscyamine.
Propantheline Propantheline Zonisamide may increase the central nervous system depressant (CNS depressant) activities of Propantheline.
Trimethoprim Trimethoprim Trimethoprim may increase the excretion rate of Zonisamide which could result in a lower serum level and potentially a reduction in efficacy.
Diltiazem Diltiazem Zonisamide may increase the arrhythmogenic activities of Diltiazem.
Nifedipine Nifedipine Zonisamide may increase the arrhythmogenic activities of Nifedipine.
Timolol Timolol The risk or severity of adverse effects can be increased when Zonisamide is combined with Timolol.
Verapamil Verapamil Zonisamide may increase the arrhythmogenic activities of Verapamil.
Atenolol Atenolol The risk or severity of bradycardia can be increased when Zonisamide is combined with Atenolol.
Pindolol Pindolol The risk or severity of bradycardia can be increased when Zonisamide is combined with Pindolol.
Cisplatin Injection Cisplatin Injection Zonisamide may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Diflunisal Diflunisal The risk or severity of adverse effects can be increased when Diflunisal is combined with Zonisamide.
Piroxicam Piroxicam Piroxicam may decrease the excretion rate of Zonisamide which could result in a higher serum level.
Bumetanide Bumetanide Bumetanide may increase the excretion rate of Zonisamide which could result in a lower serum level and potentially a reduction in efficacy.
Etoposide Etoposide The serum concentration of Etoposide can be increased when it is combined with Zonisamide.
Glyburide Glyburide The therapeutic efficacy of Glyburide can be increased when used in combination with Zonisamide.
Glipizide Glipizide The therapeutic efficacy of Glipizide can be increased when used in combination with Zonisamide.
Indapamide Indapamide Indapamide may increase the excretion rate of Zonisamide which could result in a lower serum level and potentially a reduction in efficacy.
Amoxicillin Amoxicillin Zonisamide may increase the excretion rate of Amoxicillin which could result in a lower serum level and potentially a reduction in efficacy.
Nafcillin Injection Nafcillin Injection The therapeutic efficacy of Zonisamide can be decreased when used in combination with Nafcillin.
Oxacillin Injection Oxacillin Injection Oxacillin may increase the excretion rate of Zonisamide which could result in a lower serum level and potentially a reduction in efficacy.
Pentoxifylline Pentoxifylline Zonisamide may increase the excretion rate of Pentoxifylline which could result in a lower serum level and potentially a reduction in efficacy.
Pentamidine Injection Pentamidine Injection The therapeutic efficacy of Pentamidine can be increased when used in combination with Zonisamide.
Ceftriaxone Injection Ceftriaxone Injection Ceftriaxone may decrease the excretion rate of Zonisamide which could result in a higher serum level.
Labetalol Labetalol The risk or severity of bradycardia can be increased when Labetalol is combined with Zonisamide.
Auranofin Auranofin Zonisamide may increase the excretion rate of Auranofin which could result in a lower serum level and potentially a reduction in efficacy.
Leuprolide Injection Leuprolide Injection The risk or severity of QTc prolongation can be increased when Zonisamide is combined with Leuprolide.
Gemfibrozil Gemfibrozil The metabolism of Zonisamide can be decreased when combined with Gemfibrozil.
Dipivefrin Ophthalmic Dipivefrin Ophthalmic Adefovir dipivoxil may decrease the excretion rate of Zonisamide which could result in a higher serum level.
Ceftazidime Injection Ceftazidime Injection Ceftazidime may decrease the excretion rate of Zonisamide which could result in a higher serum level.
Ketoprofen Ketoprofen The risk or severity of adverse effects can be increased when Ketoprofen is combined with Zonisamide.
Cefotetan Injection Cefotetan Injection Cefotetan may decrease the excretion rate of Zonisamide which could result in a higher serum level.
Pimozide Pimozide The metabolism of Pimozide can be decreased when combined with Zonisamide.
Enalapril Enalapril The risk or severity of hyperkalemia can be increased when Enalapril is combined with Zonisamide.
Flurbiprofen Flurbiprofen The metabolism of Zonisamide can be decreased when combined with Flurbiprofen.
Amiodarone Amiodarone The risk or severity of adverse effects can be increased when Zonisamide is combined with Amiodarone.
Aztreonam Injection Aztreonam Injection Aztreonam may increase the excretion rate of Zonisamide which could result in a lower serum level and potentially a reduction in efficacy.
Buspirone Buspirone Buspirone may increase the excretion rate of Zonisamide which could result in a lower serum level and potentially a reduction in efficacy.
Lovastatin Lovastatin The metabolism of Zonisamide can be decreased when combined with Lovastatin.
Ciprofloxacin Ciprofloxacin The metabolism of Zonisamide can be decreased when combined with Ciprofloxacin.
Mesalamine Mesalamine The risk or severity of adverse effects can be increased when Mesalazine is combined with Zonisamide.
Diclofenac Diclofenac Diclofenac may decrease the excretion rate of Zonisamide which could result in a higher serum level.
Fluoxetine Fluoxetine Fluoxetine may increase the central nervous system depressant (CNS depressant) activities of Zonisamide.
Nimodipine Nimodipine Zonisamide may increase the arrhythmogenic activities of Nimodipine.
Clozapine Clozapine The risk or severity of QTc prolongation can be increased when Zonisamide is combined with Clozapine.
Estazolam Estazolam The risk or severity of adverse effects can be increased when Zonisamide is combined with Estazolam.
Ofloxacin Ofloxacin The risk or severity of QTc prolongation can be increased when Zonisamide is combined with Ofloxacin.
Didanosine Didanosine Didanosine may increase the excretion rate of Zonisamide which could result in a lower serum level and potentially a reduction in efficacy.
Pentostatin Injection Pentostatin Injection Pentostatin may decrease the excretion rate of Zonisamide which could result in a higher serum level.
Clarithromycin Clarithromycin The metabolism of Zonisamide can be decreased when combined with Clarithromycin.
Benazepril Benazepril The risk or severity of hyperkalemia can be increased when Benazepril is combined with Zonisamide.
Etodolac Etodolac Etodolac may decrease the excretion rate of Zonisamide which could result in a higher serum level.
Felodipine Felodipine Zonisamide may increase the arrhythmogenic activities of Felodipine.
Fosinopril Fosinopril Fosinopril may increase the excretion rate of Zonisamide which could result in a lower serum level and potentially a reduction in efficacy.
Nabumetone Nabumetone Nabumetone may decrease the excretion rate of Zonisamide which could result in a higher serum level.
Pravastatin Pravastatin The serum concentration of Pravastatin can be increased when it is combined with Zonisamide.
Quinapril Quinapril The risk or severity of hyperkalemia can be increased when Quinapril is combined with Zonisamide.
Ramipril Ramipril The risk or severity of hyperkalemia can be increased when Ramipril is combined with Zonisamide.
Simvastatin Simvastatin The serum concentration of Simvastatin can be increased when it is combined with Zonisamide.
Amlodipine Amlodipine Amlodipine may increase the arrhythmogenic activities of Zonisamide.
Teniposide Injection Teniposide Injection The metabolism of Zonisamide can be decreased when combined with Teniposide.
Itraconazole Itraconazole The metabolism of Zonisamide can be decreased when combined with Itraconazole.
Lisinopril Lisinopril Lisinopril may increase the excretion rate of Zonisamide which could result in a lower serum level and potentially a reduction in efficacy.
Oxaprozin Oxaprozin Oxaprozin may decrease the excretion rate of Zonisamide which could result in a higher serum level.
Rifabutin Rifabutin The metabolism of Zonisamide can be increased when combined with Rifabutin.
Sotalol Sotalol The risk or severity of bradycardia can be increased when Zonisamide is combined with Sotalol.
Bisoprolol Bisoprolol The therapeutic efficacy of Zonisamide can be increased when used in combination with Bisoprolol.
Zolpidem Zolpidem Zonisamide may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Doxazosin Doxazosin The risk or severity of hypotension can be increased when Doxazosin is combined with Zonisamide.
Terazosin Terazosin The risk or severity of hypotension can be increased when Terazosin is combined with Zonisamide.
Isradipine Isradipine Isradipine may increase the arrhythmogenic activities of Zonisamide.
Omeprazole Omeprazole The metabolism of Zonisamide can be decreased when combined with Omeprazole.
Cisapride Cisapride The risk or severity of QTc prolongation can be increased when Cisapride is combined with Zonisamide.
Gabapentin Gabapentin The risk or severity of adverse effects can be increased when Zonisamide is combined with Gabapentin.
Fluvastatin Fluvastatin The metabolism of Zonisamide can be decreased when combined with Fluvastatin.
Venlafaxine Venlafaxine The risk or severity of adverse effects can be increased when Venlafaxine is combined with Zonisamide.
Fluvoxamine Fluvoxamine The metabolism of Zonisamide can be decreased when combined with Fluvoxamine.
Nefazodone Nefazodone The risk or severity of adverse effects can be increased when Nefazodone is combined with Zonisamide.
Lamotrigine Lamotrigine Lamotrigine may increase the arrhythmogenic activities of Zonisamide.
Losartan Losartan Zonisamide may increase the arrhythmogenic activities of Losartan.
Valacyclovir Valacyclovir Valaciclovir may decrease the excretion rate of Zonisamide which could result in a higher serum level.
Tramadol Tramadol The risk or severity of CNS depression can be increased when Zonisamide is combined with Tramadol.
Carboplatin Injection Carboplatin Injection Carboplatin may decrease the excretion rate of Zonisamide which could result in a higher serum level.
Moexipril Moexipril The risk or severity of QTc prolongation can be increased when Moexipril is combined with Zonisamide.
Lansoprazole Lansoprazole The metabolism of Zonisamide can be decreased when combined with Lansoprazole.
Ifosfamide Injection Ifosfamide Injection The metabolism of Ifosfamide can be decreased when combined with Zonisamide.
Nicardipine Nicardipine Zonisamide may increase the arrhythmogenic activities of Nicardipine.
Bupropion Bupropion The risk or severity of adverse effects can be increased when Zonisamide is combined with Bupropion.
Ticlopidine Ticlopidine The metabolism of Zonisamide can be decreased when combined with Ticlopidine.
Saquinavir Saquinavir The metabolism of Saquinavir can be decreased when combined with Zonisamide.
Metformin Metformin The risk or severity of lactic acidosis can be increased when Zonisamide is combined with Metformin.
Dalteparin Injection Dalteparin Injection The risk or severity of hyperkalemia can be increased when Zonisamide is combined with Dalteparin.
Nisoldipine Nisoldipine Nisoldipine may increase the arrhythmogenic activities of Zonisamide.
Lamivudine Lamivudine Lamivudine may increase the excretion rate of Zonisamide which could result in a lower serum level and potentially a reduction in efficacy.
Riluzole Riluzole The risk or severity of adverse effects can be increased when Riluzole is combined with Zonisamide.
Acarbose Acarbose The therapeutic efficacy of Acarbose can be increased when used in combination with Zonisamide.
Glimepiride Glimepiride Zonisamide may increase the arrhythmogenic activities of Glimepiride.
Gemcitabine Injection Gemcitabine Injection The serum concentration of Zonisamide can be increased when it is combined with Gemcitabine.
Indinavir Indinavir The metabolism of Zonisamide can be decreased when combined with Indinavir.
Ritonavir Ritonavir The serum concentration of Zonisamide can be increased when it is combined with Ritonavir.
Docetaxel Injection Docetaxel Injection The metabolism of Docetaxel can be decreased when combined with Zonisamide.
Cidofovir Injection Cidofovir Injection Cidofovir may decrease the excretion rate of Zonisamide which could result in a higher serum level.
Meropenem Injection Meropenem Injection Meropenem may increase the excretion rate of Zonisamide which could result in a lower serum level and potentially a reduction in efficacy.
Clomipramine Clomipramine The metabolism of Clomipramine can be decreased when combined with Zonisamide.
Zafirlukast Zafirlukast The metabolism of Zonisamide can be decreased when combined with Zafirlukast.
Fosfomycin Fosfomycin Fosfomycin may increase the excretion rate of Zonisamide which could result in a lower serum level and potentially a reduction in efficacy.
Mirtazapine Mirtazapine Zonisamide may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Trandolapril Trandolapril The risk or severity of hyperkalemia can be increased when Trandolapril is combined with Zonisamide.
Topiramate Topiramate The risk or severity of adverse effects can be increased when Topiramate is combined with Zonisamide.
Valsartan Valsartan The risk or severity of hyperkalemia can be increased when Valsartan is combined with Zonisamide.
Insulin Lispro Injection Insulin Lispro Injection The therapeutic efficacy of Insulin lispro can be increased when used in combination with Zonisamide.
Pramipexole Pramipexole Zonisamide may increase the sedative activities of Pramipexole.
Donepezil Donepezil The risk or severity of adverse effects can be increased when Donepezil is combined with Zonisamide.
Nelfinavir Nelfinavir The metabolism of Zonisamide can be decreased when combined with Nelfinavir.
Fexofenadine Fexofenadine The serum concentration of Fexofenadine can be increased when it is combined with Zonisamide.
Azithromycin Azithromycin The risk or severity of QTc prolongation can be increased when Zonisamide is combined with Azithromycin.
Carvedilol Carvedilol The risk or severity of bradycardia can be increased when Carvedilol is combined with Zonisamide.
Nilutamide Nilutamide The metabolism of Zonisamide can be decreased when combined with Nilutamide.
Flutamide Flutamide Flutamide may increase the excretion rate of Zonisamide which could result in a lower serum level and potentially a reduction in efficacy.
Selegiline Selegiline The risk or severity of adverse effects can be increased when Zonisamide is combined with Selegiline.
Bicalutamide Bicalutamide The metabolism of Zonisamide can be decreased when combined with Bicalutamide.
Sertraline Sertraline The risk or severity of adverse effects can be increased when Zonisamide is combined with Sertraline.
Propafenone Propafenone The risk or severity of bradycardia can be increased when Zonisamide is combined with Propafenone.
Letrozole Letrozole The metabolism of Zonisamide can be decreased when combined with Letrozole.
Irbesartan Irbesartan The risk or severity of hyperkalemia can be increased when Zonisamide is combined with Irbesartan.
Tamsulosin Tamsulosin The risk or severity of hypotension can be increased when Tamsulosin is combined with Zonisamide.
Ropinirole Ropinirole Zonisamide may increase the sedative activities of Ropinirole.
Finasteride Finasteride The metabolism of Finasteride can be decreased when combined with Zonisamide.
Quetiapine Quetiapine Zonisamide may increase the central nervous system depressant (CNS depressant) activities of Quetiapine.
Cefepime Injection Cefepime Injection Cefepime may decrease the excretion rate of Zonisamide which could result in a higher serum level.
Cefprozil Cefprozil Cefprozil may decrease the excretion rate of Zonisamide which could result in a higher serum level.
Cefpodoxime Cefpodoxime Cefpodoxime may decrease the excretion rate of Zonisamide which could result in a higher serum level.
Cetirizine Cetirizine The risk or severity of adverse effects can be increased when Cetirizine is combined with Zonisamide.
Paroxetine Paroxetine The risk or severity of adverse effects can be increased when Zonisamide is combined with Paroxetine.
Tolcapone Tolcapone The risk or severity of adverse effects can be increased when Tolcapone is combined with Zonisamide.
Citalopram Citalopram The risk or severity of QTc prolongation can be increased when Zonisamide is combined with Citalopram.
Capecitabine Capecitabine Zonisamide may increase the excretion rate of Capecitabine which could result in a lower serum level and potentially a reduction in efficacy.
Efavirenz Efavirenz The serum concentration of Zonisamide can be decreased when it is combined with Efavirenz.
Abacavir Abacavir Zonisamide may increase the excretion rate of Abacavir which could result in a lower serum level and potentially a reduction in efficacy.
Sildenafil Sildenafil The metabolism of Sildenafil can be decreased when combined with Zonisamide.
Pioglitazone Pioglitazone The therapeutic efficacy of Pioglitazone can be increased when used in combination with Zonisamide.
Celecoxib Celecoxib Celecoxib may decrease the excretion rate of Zonisamide which could result in a higher serum level.
Rosiglitazone Rosiglitazone The therapeutic efficacy of Rosiglitazone can be increased when used in combination with Zonisamide.
Tolterodine Tolterodine Zonisamide may increase the central nervous system depressant (CNS depressant) activities of Tolterodine.
Thalidomide Thalidomide Zonisamide may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Oseltamivir Oseltamivir Oseltamivir may increase the excretion rate of Zonisamide which could result in a lower serum level and potentially a reduction in efficacy.
Colesevelam Colesevelam Colesevelam can cause a decrease in the absorption of Zonisamide resulting in a reduced serum concentration and potentially a decrease in efficacy.
Balsalazide Balsalazide The risk or severity of adverse effects can be increased when Balsalazide is combined with Zonisamide.
Nateglinide Nateglinide The therapeutic efficacy of Nateglinide can be increased when used in combination with Zonisamide.
Galantamine Galantamine The risk or severity of QTc prolongation can be increased when Galantamine is combined with Zonisamide.
Levetiracetam Levetiracetam The risk or severity of adverse effects can be increased when Zonisamide is combined with Levetiracetam.
Rabeprazole Rabeprazole The metabolism of Zonisamide can be decreased when combined with Rabeprazole.

Content provided by: AHFS® Patient Medication Information™. © Copyright, 2021. The American Society of Health-System Pharmacists